Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Zhonghua Yi Xue Za Zhi ; 104(7): 514-520, 2024 Feb 20.
Article in Chinese | MEDLINE | ID: mdl-38317363

ABSTRACT

Objective: To investigate the therapeutic effect and prognostic value of oligoclonal bands (OB) in multiple myeloma (MM) patients after autologous stem cell transplant (ASCT). Methods: The data of 156 patients with MM who underwent ASCT after inductive treatment in the Department of Hematology, Jiangsu Provincial People's Hospital from December 2013 to February 2022 were retrospectively analyzed, including 91 males and 65 females. The median age was 56 (26, 71) years. Patients were divided into two groups according to OB formation after ASCT treatment, including OB group (n=60) and non-OB group (n=96). The last follow-up date was August 31, 2023, and the follow-up period was 42 (18, 117) months. The clinical baseline characteristics and efficacy of the two groups were compared. Progression-free survival (PFS) and overall survival (OS) were compared between the two groups by Kaplan-Meier method. Cox risk regression modal was used to analyze the risk factors associated with prognosis. Results: There were no significant differences in age, type, stage, risk stratification, extramedullary disease (EMD), proportion of circulating plasma cells and induction therapy regimen between OB and non-OB groups (all P>0.05). The proportion of patients in OB group who achieved complete response (CR) or above after ASCT treatment was 93.3% (56/60), which was higher than that in non-OB group (80.2%, 77/96) (P=0.024). The negative rate of minimal residual disease (MRD) in OB group was 66.7% (40/60), which was higher than that in non-OB group (34.4%, 33/96) (P=0.001). The median PFS and OS in the OB group were not reached, and the median PFS and OS in the non-OB group were 28 (2, 80) months and 86 (2, 100) months, respectively. The PFS (P<0.001) and OS (P=0.017) of patients with OB were considerably longer. In the Cox multivariate analysis, OB was an independent prognostic factor for PFS in MM patients (HR=0.314, 95%CI: 0.153-0.644, P=0.002). Subgroup analysis showed that among high-risk patients with mSMART, the OS of patients in OB group was not reached, which was significantly better than that of non-OB group [71 (2, 90) months, P=0.046]. However, no significant difference was observed in the OS of patients with OB and those with non-OB in standard risk group (not reached vs not reached, P=0.103). In those with EMD at diagnosis, patients with OB had significantly better OS than those with non-OB [not reached vs 47 (6, 74) months, P=0.037]. However, no significant difference was observed in the OS of patients with OB and those with non-OB in those without EMD at diagnosis [not reached vs 86 (2, 100) months, P=0.130]. Conclusions: OB formation after ASCT treatment in MM patients is related to the efficacy and prognosis. OB formation can increase the negative MRD rate, prolong the OS and improve the prognosis, especially for newly diagnosed patients with extramedullary disease or patients with high-risk genetic characteristics.


Subject(s)
Hematopoietic Stem Cell Transplantation , Multiple Myeloma , Male , Female , Humans , Middle Aged , Prognosis , Multiple Myeloma/therapy , Multiple Myeloma/diagnosis , Treatment Outcome , Oligoclonal Bands/therapeutic use , Retrospective Studies , Transplantation, Autologous , Stem Cell Transplantation
2.
Intern Med ; 61(24): 3733-3738, 2022 Dec 15.
Article in English | MEDLINE | ID: mdl-35598995

ABSTRACT

Central nervous system methotrexate-associated lymphoproliferative disorder (CNS-MTX-LPD) is rare, but its spontaneous regression has been observed in some patients after withdrawal of agents. We herein report three cases of primary CNS-MTX-LPD that received oral MTX for rheumatoid arthritis. Epstein-Barr virus and oligoclonal bands (OCBs) were positive, while proton magnetic resonance spectroscopy (1H-MRS) showed an elevated lipid peak and slightly elevated choline/N-acetylaspartate ratio in common. After MTX withdrawal, brain lesions showed spontaneous regression in all cases. Our patient's 1H-MRS findings and OCBs may reflect a non-monoclonal lymphoproliferative histology as benign-type lesions in CNS-MTX-LPD.


Subject(s)
Antirheumatic Agents , Epstein-Barr Virus Infections , Lymphoproliferative Disorders , Humans , Methotrexate/adverse effects , Oligoclonal Bands/therapeutic use , Antirheumatic Agents/therapeutic use , Epstein-Barr Virus Infections/pathology , Herpesvirus 4, Human , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/diagnostic imaging , Lymphoproliferative Disorders/drug therapy , Prognosis , Central Nervous System/pathology , Magnetic Resonance Spectroscopy
3.
Mult Scler Relat Disord ; 25: 131-137, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30071507

ABSTRACT

Since their discovery, the existence of secreted oligoclonal immunoglobulin in the central nervous system in people with multiple sclerosis has been the subject of scientific investigation and debate over several decades. Although autoantibodies can be detected in some individuals, probably secondary to release of neo-antigens after damage, evidence for a major, primary involvement of damaging antibodies is still relatively lacking. However, it is possible to construct a working hypothesis that establishes the interaction of plasma cells, which are the source of oligoclonal bands, microglia and astrocytes to create a self-perpetuating activated phenotype. This may generate an environment conducive to long-term plasma cell survival and the initiation and perpetuation of neurotoxicity that may contribute to disease worsening in multiple sclerosis. Therapeutic strategies to re-establish a homeostatic environment conducive to repair/recovery are indicated to control progressive multiple sclerosis.


Subject(s)
Multiple Sclerosis , Oligoclonal Bands/therapeutic use , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Agammaglobulinaemia Tyrosine Kinase/metabolism , Animals , Enzyme Inhibitors/therapeutic use , Humans , Microglia/drug effects , Microglia/metabolism , Multiple Sclerosis/immunology , Multiple Sclerosis/metabolism , Multiple Sclerosis/therapy , Receptors, Fc/immunology
4.
Curr Opin Immunol ; 40: 51-61, 2016 06.
Article in English | MEDLINE | ID: mdl-26995095

ABSTRACT

Monoclonal antibodies (mAbs) have revolutionized the diagnosis and treatment of many human diseases and the application of combinations of mAbs has demonstrated improved therapeutic activity in both preclinical and clinical testing. Combinations of antibodies have several advantages such as the capacities to target multiple and mutating antigens in complex pathogens and to engage varied epitopes on multiple disease-related antigens (e.g. receptors) to overcome heterogeneity and plasticity. Oligoclonal antibodies are an emerging therapeutic format in which a novel antibody combination is developed as a single drug product. Here, we will provide historical context on the use of oligoclonal antibodies in oncology and infectious diseases and will highlight practical considerations related to their preclinical and clinical development programs.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Immunotherapy/methods , Infections/therapy , Neoplasms/therapy , Oligoclonal Bands/therapeutic use , Recombinant Proteins/therapeutic use , Animals , Antigenic Modulation , Antigenic Variation , Drug Evaluation, Preclinical , Humans , Infections/immunology , Neoplasms/immunology
5.
Br J Pharmacol ; 173(9): 1407-24, 2016 May.
Article in English | MEDLINE | ID: mdl-26833433

ABSTRACT

Antibody-based therapy of cancer employs monoclonal antibodies (mAbs) specific to soluble ligands, membrane antigens of T-lymphocytes or proteins located at the surface of cancer cells. The latter mAbs are often combined with cytotoxic regimens, because they block survival of residual fractions of tumours that evade therapy-induced cell death. Antibodies, along with kinase inhibitors, have become in the last decade the mainstay of oncological pharmacology. However, partial and transient responses, as well as emergence of tumour resistance, currently limit clinical application of mAbs. To overcome these hurdles, oligoclonal antibody mixtures are being tested in animal models and in clinical trials. The first homo-combination of two mAbs, each engaging a distinct site of HER2, an oncogenic receptor tyrosine kinase (RTK), has been approved for treatment of breast cancer. Likewise, a hetero-combination of antibodies to two distinct T-cell antigens, PD1 and CTLA4, has been approved for treatment of melanoma. In a similar vein, additive or synergistic anti-tumour effects observed in animal models have prompted clinical testing of hetero-combinations of antibodies simultaneously engaging distinct RTKs. We discuss the promise of antibody cocktails reminiscent of currently used mixtures of chemotherapeutics and highlight mechanisms potentially underlying their enhanced clinical efficacy.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Immunotherapy , Neoplasms/immunology , Neoplasms/therapy , Oligoclonal Bands/immunology , Oligoclonal Bands/therapeutic use , Antineoplastic Agents/immunology , Humans
7.
J Neuroimmunol ; 264(1-2): 100-5, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-24125567

ABSTRACT

We investigated the impact of disease duration, clinical course and immunosuppressive therapy on intrathecal IgG synthesis in multiple sclerosis (MS). Cerebrospinal fluid (CSF) was obtained twice, 8-10 years apart, from 20 MS patients and 26 healthy controls, and from 22 MS patients before and after two years of mitoxantrone treatment. The oligoclonal IgG band patterns changed in 15 patients at long-term follow-up, but were only influenced in 4 patients by mitoxantrone therapy. The CSF B-cell-regulating chemokine CXCL13 correlated with intrathecal IgG production suggesting a B-cell-dependence of intrathecal IgG synthesis in MS.


Subject(s)
Immunosuppression Therapy/methods , Multiple Sclerosis/drug therapy , Oligoclonal Bands/therapeutic use , Adolescent , Adult , Chemokine CXCL13/metabolism , Disability Evaluation , Enzyme-Linked Immunosorbent Assay , Female , Humans , Injections, Spinal , Longitudinal Studies , Male , Middle Aged , Mitoxantrone/therapeutic use , Multiple Sclerosis/cerebrospinal fluid , Oligoclonal Bands/cerebrospinal fluid , Severity of Illness Index , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...